RecruitingEarly Phase 1NCT05008146

Imaging CRF X NOP Interactions in CUD

Imaging Corticotrophin-releasing Factor (CRF) X Nociceptive Opioid Peptide (NOP) Interactions in Cocaine Use Disorders (Aim 1)


Sponsor

Rajesh Narendran

Enrollment

80 participants

Start Date

Dec 31, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

This study uses \[11C\]NOP-1A positron emission tomography (PET) and a hydrocortisone challenge to image the interaction between nociceptive opioid peptide (NOP) receptors and cortisol/corticotrophin releasing factor (CRF) in subjects with cocaine use disorders (CUD) and matched healthy controls (HC). It will also examine whether alterations in CRF x NOP interactions predict relapse in subjects with CUD.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria14

  • Cocaine use disorders (CUD)
  • Males or females between 18 and 55 years old
  • Fulfil DSM-5 criteria for cocaine use disorder
  • No other current DSM-5 psychiatric or addictive disorders (such as major depressive disorder, bipolar disorders, psychotic disorders, etc.,)
  • No current abuse (six months) of opiates, sedative-hypnotics, amphetamines, MDMA, etc., as well as moderate to severe alcohol or cannabis use (twice a week). Nicotine use will be quantified and controlled between groups using the Fagerstrom Test for Nicotine Dependence (Heatherton et al., 1991);
  • Not currently on prescription medical or psychotropic medications
  • No current or past severe medical, endocrine or neurological illnesses including glaucoma, seizure disorders, hypertension, hypercholesterolemia as assessed by a complete medical history and physical
  • Not currently pregnant or breastfeeding
  • No history of significant radioactivity exposure in past year from another research study or occupation that exceeds RDRC guidelines
  • No metallic objects in the body that are contraindicated for MRI
  • Healthy Controls (HC)
  • Males or females between 18 and 55 years old
  • No present or past DSM-5 disorders (other than nicotine dependence)
  • Criteria 5 to 9 as listed previously.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONBaseline [C-11]NOP-1A PET Scan

Radiotracer

DRUGHydrocortisone

Intravenous, 1mg/Kg

RADIATIONPost-hydrocortisone [C-11]NOP-1A PET Scan

Radiotracer


Locations(1)

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05008146


Related Trials